Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7272   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2016-001643-39
    Sponsor's Protocol Code Number:2215-CL-0302
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2018-02-12
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2016-001643-39
    A.3Full title of the trial
    A Phase 3 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Effectiveness and safety of gilteritinib (ASP2215) as maintenance treatment (maintain the response achieved during the first course of treatment) for Acute myeloid leukemia patients who are in a first complete remission (no residual leukemia cells in your bone marrow), with mutations in the FLT3 gene compared to placebo given alone.

    Évaluer la sécurité d'emploi et l'efficacité du Gilteritinib (ASP2215) comme le traitement d'entretien (maintenir la réponse obtenue au cours du premier traitement) chez des patients atteints de LAM présentant des mutations du gène de la tyrosine kinase analogue à FMS 3 (FLT3) lors d'une première rémission (absence de la leucémie aiguë dans la moelle osseuse) comparant à un placebo.
    A.4.1Sponsor's protocol code number2215-CL-0302
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstellas Pharma Global Development, Inc. (APGD)
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstellas Pharma Global Development, Inc. (APGD)
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstellas Pharma Europe B.V.
    B.5.2Functional name of contact pointService Desk - Global Clinical Dev.
    B.5.3 Address:
    B.5.3.1Street AddressSylviusweg 62
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 BE
    B.5.4Telephone number+31715455878
    B.5.5Fax number+31715455224
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGilteritinib
    D.3.2Product code ASP2215
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeASP2215
    D.3.9.4EV Substance CodeSUB177203
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects diagnosed with FLT3/ITD acute myeloid leukemia (AML) in CR1, including CRp and CRi, for whom a decision not to proceed with transplantation has been made, or a suitable donor could not be identified.
    Patients atteints de LAM présentant des mutations FLT3/ITD en Première rémission complète (CR1) pour qui la décision de ne pas procéder à une transplantation sera prise ou si un donneur compatible n'a pas pu être identifié.
    E.1.1.1Medical condition in easily understood language
    AML is cancer of myeloid line of blood cells characterized by rapid growth of abnormal white blood cells that accumulate in bone marrow and interfere with production of normal blood cells.
    LMA est un cancer de la lignée myéloïde des leucocytes qui se caractérise par un envahissement médullaire de cellules immatures dû à un blocage de maturation des globules blancs dans la moelle osseuse
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10000886
    E.1.2Term Acute myeloid leukemia
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to compare relapse-free survival (RFS) between subjects with FLT3/ITD AML in first complete remission (CR1) without transplant and who are randomized to receive gilteritinib or placebo beginning after completion of induction/consolidation chemotherapy for a 2-year period.
    L'objectif principal est de comparer la survie sans récidive (SSR) entre des patients atteints de LAM présentant des mutations de type duplication interne en tandem (ITD) du gène de la tyrosine kinase analogue à FMS 3 (FLT3) lors d'une première rémission complète (CR) en l'absence de transplantation et qui sont randomisés pour recevoir le Gilteritinib ou un placebo initié après la fin de la chimiothérapie d'induction/de consolidation pendant une période de 2 ans.
    E.2.2Secondary objectives of the trial
    Key Secondary Objective:
    ●Compare overall survival (OS) in subjects treated with gilteritinib as maintenance therapy after induction/consolidation with those treated with placebo.
    Additional Secondary Objectives:
    ●Event-free survival (EFS), AEs, clinical laboratory, vital signs, electrocardiograms (ECGs) and Eastern Cooperative Oncology Group (ECOG) performance scores.
    ● Examine the relationship of minimal residual disease (MRD), as determined using a next-generation sequencing (NGS) platform specific to FLT3/ITD mutations, with RFS and OS.
    Le principal objectif secondaire consiste à :
    -Comparer la SG chez les patients recevant un traitement d'entretien par Gilteritinib après un traitement d'induction/de consolidation avec ceux traités par placebo.
    Les objectifs secondaires consistent à :
    Évaluer la sécurité d'emploi et l'efficacité du Gilteritinib par rapport au placebo en termes de :
    - Survie sans événement (SSE), événements indésirables (EI), paramètres cliniques de laboratoire, signes vitaux, électrocardiogrammes (ECG) et scores de performance de l'ECOG (Eastern Cooperative Oncology Group).
    -Examiner la relation entre une maladie résiduelle minimale (MRM), déterminée à l'aide d'une plateforme de séquençage de dernière génération (NGS) spécifique aux mutations FLT3/ITD, et la SSR et l'SG.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Retrospective Pharmacogenomics Substudy (Optional)
    The PGx research that may be conducted in the future with acquired blood samples and/or buccal swab is exploratory. The objective of this research will be to analyze or determine genes of relevance to clinical response, pharmacokinetics, and toxicity/safety issues. By analyzing genetic variations, it may be possible to predict an individual subject’s response to treatment in terms of efficacy and/or toxicity.

    Pharmacokinetic sampling substudy:
    Sparse (predose) pharmacokinetic samples will be collected in all subjects.
    Additional ECGs and/or time-matched plasma samples will be collected in a subset of approximately 90 subjects (targeting approximately 60 subjects in the gilteritinib arm and 30 subjects in the placebo arm) at the following visits and time points:
    ● Day 15 – 4 hours (± 1 hour) postdose
    ● Day 29 – 4 hours (± 1 hour) postdose
    E.3Principal inclusion criteria
    1. Written informed consent must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
    2. Subject is considered an adult according to local regulation at the time of signing informed consent form (ICF).
    3. Subject consents to allow access to his or her diagnostic bone marrow aspirate or peripheral blood sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic test that is being developed in parallel with gilteritinib.
    4. Subject has confirmed morphologically documented AML in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as < 5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.
    5. Subject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or by the patient or a suitable donor could not be identified.
    6. Subject is < 2 months from the start of the last cycle of consolidation and should have completed the recommended number of consolidations per local practice.
    7. Subject has had no use of investigational agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.
    8. Subject has had presence of the FLT3/ITD activating mutation in the bone marrow or peripheral blood as determined by the local institution at diagnosis.
    9. Subject has an ECOG performance status 0 to 2.
    10. Subject must meet the following criteria as indicated on the clinical laboratory tests:
    ● Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
    ● Serum total bilirubin ≤ 2.5 mg/dL, except for subjects with Gilbert’s syndrome.
    ● Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.
    ● Serum potassium and serum magnesium ≥ institutional lower limit of normal (LLN).
    ● Absolute neutrophil count (ANC) ≥ 500/μl and platelets ≥ 20000/μl (unsupported by transfusions).
    11. Subject is suitable for oral administration of study drug.

    For Inclusion Criteria 12-17 see Protocol
    1-Un consentement éclairé doivent être obtenus du patient ou de son représentant légal avant de réaliser toute procédure liée à l'étude (y compris l'arrêt des médicaments interdits, le cas échéant).
    2-Le patient est considéré comme un adulte conformément à la réglementation locale au moment de la signature du formulaire de consentement éclairé (FCE)
    3-Le patient consent à autoriser l'accès à son échantillon de moelle osseuse obtenu par aspiration à des fins de diagnostic ou à son échantillon de sang périphérique et/ou son ADN provenant de cet échantillon, s'il est disponible, qui peut être utilisé pour valider un test diagnostique compagnon qui est développé en parallèle avec le Gilteritinib.
    4-Le patient a une LAM confirmée et morphologiquement documentée en CR1 (y compris CRp et CRi). Pour l'inclusion, la CR sera définie comme la présence de < 5% de blastes dans la moelle osseuse en l'absence de caractéristiques morphologiques de la leucémie aiguë (par exemple, bâtonnets d'Auer) dans la moelle osseuse sans signe de maladie extramédullaire comme une atteinte du système nerveux central ou un sarcome granulocytaire
    5-Le patient ne subira pas de transplantation car une décision de ne pas réaliser de transplantation a été prise sur la recommandation du médecin traitant ou par le patient lui-même ou car aucun donneur compatible n'a pu être identifié
    6-Le patient a débuté le dernier cycle du traitement de consolidation depuis < 2 mois et doit avoir terminé le nombre recommandé de consolidations conformément aux normes locales en vigueur.
    7-Le patient n'a pas eu recours à des agents expérimentaux, à l'exception des agents inhibant FLT3 pendant le traitement d'induction et/ou de consolidation, au cours des 4 semaines précédentes.
    8-Le patient présente une mutation activatrice FLT3/ITD dans la moelle osseuse ou le sang périphérique déterminée par l'établissement local au moment du diagnostic.
    9-Le patient a un statut de performance de l'ECOG compris entre 0 et 2.
    10-Le patient doit satisfaire les critères suivants indiqués sur les analyses cliniques de laboratoire :
    -Créatininémie ≤ 1,5 x la limite supérieure de la normale (LSN), ou si la créatinine sérique est en dehors des valeurs normales, le taux de filtration glomérulaire (DFG) calculé à l'aide de l'équation Modification of diet in renal disease (MDRD) à 4 paramètres doit être > 40 ml/min/1,73 m2.
    -Bilirubine sérique totale ≤ 2,5 mg/dl, sauf pour les patients atteints du syndrome de Gilbert.
    -Aspartate aminotransférase (AST) et alanine aminotransférase (ALT) sériques < 3 x la LSN.
    -Taux sériques de potassium et de magnésium ≥ à la limite inférieure de la normale (LIN) de l'établissement.
    -Numération absolue des polynucléaires neutrophiles (NAPN) ≥ 500/μl et numération plaquettaire ≥ 20 000/μl (non pris en charge par des transfusions).
    11- Le patient peut recevoir le médicament à l'étude par voie orale.

    Cf protocole pour les critères d'inclusion 12-17
    E.4Principal exclusion criteria
    1.Subject has had prior allogeneic transplant.
    2. Subject has QTcF interval > 450 msec (average of triplicate determinations).
    3. Subject with Long QT Syndrome.
    4. Subject with hypokalemia and hypomagnesemia at screening (defined as values below LLN).
    5. Subject has clinically active central nervous system leukemia.
    6. Subject is known to have human immunodeficiency virus infection.
    7. Subject has active hepatitis B or C.
    8. Subject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.
    9. Subject has progressing infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
    10. Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 1 month prior to study entry results in a left ventricular ejection fraction that is ≥ 45%.
    11. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
    12. Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
    13. Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.

    For Exclusion Criteria 14-16 see Protocol
    1. Le patient a subi une greffe allogénique précédemment.
    2. Le patient présente un intervalle QTcF > 450 msec (moyenne de trois déterminations).
    3. Le patient est atteint du syndrome du QT long.
    4. Le patient présente une hypokaliémie et une hypomagnésémie lors de la sélection (définies comme des valeurs inférieures à la LIN).
    5. Le patient a une leucémie du système nerveux central active sur le plan clinique.
    6. Le patient a une infection connue par le virus de l'immunodéficience humaine.
    7. Le patient a une hépatite B ou C active.
    8. Le patient a une infection non contrôlée. Si une infection bactérienne ou virale est présente, le patient doit recevoir un traitement définitif et ne doit présenter aucun signe d'infection progressive pendant les 72 heures précédant la randomisation. Si une infection fongique est présente, le patient doit recevoir un traitement systémique antifongique définitif et ne doit présenter aucun signe d'infection progressive pendant la semaine précédant la randomisation.
    9. Le patient a une infection progressive définie comme une instabilité hémodynamique attribuable à une septicémie ou à de nouveaux symptômes, une aggravation des signes physiques ou des résultats radiographiques attribuable à une infection. Une fièvre persistante sans autres signes ou symptômes ne sera pas interprétée comme une infection progressive.
    10. Le patient a une angine non contrôlée, une arythmie ventriculaire sévère non contrôlée, un signe électrocardiographique d'ischémie aiguë, une insuffisance cardiaque congestive de classe 3 ou 4 selon les critères de la New York Heart Association (NYHA) ou le patient a des antécédents d'insuffisance cardiaque congestive de classe 3 ou 4 selon les critères de la NYHA, à moins qu'une échocardiographie ou une angiographie isotopique préalable réalisée dans le mois précédant l'entrée dans l'étude ne montre que la fraction d'éjection ventriculaire gauche est ≥ 45 %.
    11. Le patient nécessite un traitement médicamenteux concomitant avec de puissants inducteurs du cytochrome P450 (CYP) 3A.
    12. Le patient nécessite un traitement médicamenteux concomitant avec de puissants inhibiteurs ou inducteurs de la glycoprotéine P (gp-P) à l'exception des médicaments considérés comme absolument essentiels aux soins du patient.
    13. Le patient nécessite un traitement médicamenteux concomitant ciblant le récepteur 1 de la sérotonine ou 5-hydroxytryptamine (5HT1R) ou le récepteur 2B de la 5-hydroxytryptamine (5HT2BR) ou le récepteur non spécifique sigma à l'exception des médicaments considérés comme absolument essentiels aux soins du patient.

    Cf protocole pour les Critères d'exclusion 14-16
    E.5 End points
    E.5.1Primary end point(s)
    Relapse-free survival (RFS)
    Leukemia relapse will be defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extramedullary blast foci as per Revised International Working Group (IWG) criteria.
    Survie sans rechute (SSR)
    Une récidive de la leucémie sera définie comme la présence de 5 % ou plus de blastes dans la moelle osseuse (non attribuables à la régénération de la moelle osseuse), la présence de blastes circulants, la présence d'un foyer extramédullaire de blastes selon les critères révisés du groupe de travail international
    E.5.1.1Timepoint(s) of evaluation of this end point
    RFS: the time from randomization until relapse or death from any cause, whichever comes first.
    SSR définie comme le temps écoulé entre la randomisation et la récidive ou le décès toutes causes confondues, selon la première éventualité.
    E.5.2Secondary end point(s)
    Key Secondary Endpoints:
    ● Overall survival (OS)
    Additional secondary efficacy endpoints:
    ● Event-free survival (EFS)
    ● Minimal residual disease (MRD)
    Safety Endpoints
    ● AEs
    ● Serum chemistry, hematology, coagulation and urinalysis
    ● Vital signs
    ● ECGs
    ● Physical examination findings
    ● Eastern Cooperative Oncology Group (ECOG) performance status
    Critères d’évaluation secondaires:
    -SG, définie comme le temps écoulé entre la randomisation et le décès toutes causes confondues
    Les critères d'évaluation secondaires sont :
    -La SSE
    -La MRM
    Critères d’évaluation de la sécurité d'emploi:
    -Biochimie sérique, hématologie, coagulation et analyse d'urine
    -Signes vitaux
    -Résultats de l'examen clinique
    -Statut de performance de l'ECOG
    E.5.2.1Timepoint(s) of evaluation of this end point
    OS: the time from randomization until death from any cause.
    SG, définie comme le temps écoulé entre la randomisation et le décès toutes causes confondues.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned16
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA111
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Czech Republic
    Korea, Democratic People's Republic of
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of trial in all participating countries is defined as the last subject’s last contact.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 500
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 55
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 308
    F.4.2.2In the whole clinical trial 555
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-01-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-12-13
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands